Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
Related Posts
Murrell DF, Weinberg JM, Yamauchi PS, Abdelmaksoud A, Grabbe S, Goldust M. Predatory Conferences and Journals in Dermatology Are Black Widow Parties. Skinmed. 2024 Oct[...]
Wottrich S, Mendonca S, Safarpour C, Nguyen C, Marinelli LJ, Hancock SP, Modlin RL, Parker JM. Putative pseudolysogeny-dependent phage gene implicated in the superinfection resistance[...]
Hao A, Yu RP, Kikuchi R, Sadrolashrafi K, Guo L, Yamamoto RK, Tolson H, Yee D, Bilimoria S, Pourali SP, Adler BL, Armstrong AW. Contact[...]